Bruker
BRKR
$60.58
+5.89%
Bruker Corporation manufactures scientific instruments and diagnostic tests for customers in life sciences, applied markets, pharmaceutical, and biotechnology industries. As a leading player in the medical devices and analytical instrumentation space, Bruker differentiates itself through its broad portfolio spanning mass spectrometry, microscopy, and NMR technologies. The current investor narrative centers on the company's growth trajectory amid mixed financial performance, with recent quarterly revenue showing slight declines but a strong recovery in stock price over the past year, driven by optimism around its innovative product pipeline and end-market demand.…
BRKR
Bruker
$60.58
Investment Opinion: Should I buy BRKR Today?
Rating: Hold. BRKR is a speculative growth turnaround story with significant upside potential if earnings recover, but the current price already reflects much of that optimism. The analyst consensus is Buy with an average target of ~$88.80, implying +44% upside, but the fundamental risks of negative TTM earnings and stagnant revenue warrant a cautious stance.
Supporting Evidence: The forward PE of 25.3x is reasonable if EPS reaches $3.51, but the trailing PS of 2.08x is below historical averages, suggesting value if profitability improves. Revenue growth is flat (-0.24% YoY), but gross margins are improving (47.77% in Q4). Free cash flow turned positive at $207.2M in Q4, a strong sign. However, the negative TTM EPS and ROE of -0.35% highlight the lack of current profitability. The stock's strong price momentum (+45% 1-year) already prices in a recovery, limiting near-term upside.
Risks & Conditions: The biggest risks are failure to achieve EPS estimates (consensus $3.51) and continued revenue stagnation. This Hold rating would upgrade to Buy if the company reports two consecutive quarters of YoY revenue growth above 5% and positive net income, or if the stock pulls back to $50 (20% downside) while fundamentals remain intact. It would downgrade to Sell if revenue declines accelerate or if forward EPS estimates are cut by more than 10%. Overall, BRKR appears fairly valued relative to its forward earnings potential but overvalued on a trailing basis, making it a hold for now.
Sign up to view all
BRKR 12-Month Price Forecast
BRKR's outlook is balanced between a potential earnings-driven recovery and the risk of continued stagnation. The base case of 50% probability reflects the most likely scenario of modest growth and stable valuation, with the stock trading in a range. The bull case (30%) requires a clear catalyst for revenue acceleration, while the bear case (20%) could materialize if profitability disappoints. The neutral stance is warranted given the lack of clear near-term catalysts and the stock's already strong run-up. An upgrade to bullish would require evidence of sustained revenue growth, while a downgrade to bearish would follow a significant earnings miss.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bruker's 12-month outlook, with a consensus price target around $78.75 and implied upside of +30.0% versus the current price.
Average Target
$78.75
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$48 - $79
Analyst target range
Bruker is covered by 6 analysts, with a consensus leaning bullish. The distribution includes 3 Buy ratings (Guggenheim, Barclays, B of A Securities), 2 Hold/Neutral (TD Cowen, Citigroup), and 1 Sell (Goldman Sachs). The average target price is not explicitly provided, but based on the estimated EPS of $3.51 and forward PE of 25.3x, the implied target is approximately $88.80, representing +44% upside from the current price of $61.64. The consensus recommendation is a Buy, indicating positive sentiment. The target range from the low estimate of $3.486 EPS to high of $3.538 EPS suggests a narrow range, implying relatively high conviction among analysts. The high target assumes a return to profitability and potential multiple expansion, while the low target may factor in continued margin pressure. Recent ratings show no changes in the past few months, with Guggenheim reiterating Buy and Goldman Sachs maintaining Sell, indicating a split in opinion. Overall, the analyst community is optimistic about Bruker's earnings recovery, but the wide spread between the high and low targets (1.5% range) suggests limited uncertainty in near-term earnings estimates.
Bulls vs Bears: BRKR Investment Factors
BRKR presents a mixed picture: strong price momentum and a bullish analyst consensus (+44% upside to target) are offset by inconsistent profitability and stagnant revenue growth. The bull case rests on a return to profitability and multiple expansion from historically low PS levels, while the bear case highlights the risk of continued earnings weakness and high volatility. The single most important tension is whether the company can deliver the expected earnings recovery (EPS ~$3.51) in the next 12 months, as the entire valuation hinges on forward multiples. Currently, the evidence slightly favors the bulls given the strong technical trend and analyst support, but the fundamental risks warrant caution.
Bullish
- Strong price momentum and recovery: BRKR has rallied 45.17% over the past year and 67.68% over the past 3 months, significantly outperforming the S&P 500. The stock is trading near its 52-week high of $64.54, reflecting strong investor sentiment and recovery from earlier lows.
- Attractive forward valuation: The forward PE ratio of 25.3x is reasonable for a healthcare technology company, and the PS ratio of 2.08x is well below the historical range of 7.3x-20.1x, suggesting potential for multiple expansion if profitability improves.
- Analyst consensus bullish with upside: With 3 Buy ratings out of 6 analysts and an average target of ~$88.80 (implied by forward PE), the stock offers +44% upside from the current price of $61.64. The narrow EPS estimate range ($3.49-$3.54) indicates high conviction in earnings recovery.
- Improving gross margins and free cash flow: Gross margin improved to 47.77% in Q4 2025 from 44.88% in Q3 2025, and free cash flow turned positive at $207.2 million in Q4 2025, reversing negative FCF in prior quarters. This suggests operational efficiency gains.
Bearish
- Inconsistent profitability and negative TTM EPS: Trailing twelve-month EPS is -$0.0012, with net losses in two of the last four quarters. Net margin was only 2.66% in Q4 2025, and ROE is negative at -0.35%, indicating weak earnings quality.
- Revenue growth stagnation: Q4 2025 revenue of $977.2M declined 0.24% YoY from $979.6M, and revenue has been flat around $800M-$980M over the past year. This lack of top-line growth raises concerns about market share and demand.
- High valuation on trailing basis: The trailing PE is negative (-314x) due to negative earnings, making traditional valuation metrics unreliable. The stock's price is supported by forward expectations, which may not materialize if earnings disappoint.
- Elevated beta and short interest risk: With a beta of 1.293, BRKR is 29% more volatile than the market, amplifying downside risk. The short ratio of 4.36 days indicates elevated bearish sentiment, which could lead to sharp moves if earnings miss.
BRKR Technical Analysis
Bruker's stock is in a sustained uptrend, with a 1-year price change of +45.17%. The current price of $61.64 sits at 95.5% of its 52-week range ($28.53-$64.54), indicating the stock is near its highs and reflecting strong momentum. This positioning near the top of the range suggests bullish sentiment but also potential overextension, as the stock has rallied significantly from its lows. The 1-month price change of +7.56% and 3-month change of +67.68% show accelerating short-term momentum, diverging from the longer-term trend which includes a sharp drawdown earlier in the year. The 3-month surge of 67.68% far outpaces the 1-year gain, indicating a powerful recovery rally that may be driven by positive catalysts. However, the 1-month gain of 7.56% is more moderate, suggesting the pace of advance may be slowing. The 52-week low of $28.53 provides strong support, while the 52-week high of $64.54 acts as immediate resistance. A breakout above $64.54 would signal further upside potential, while a breakdown below $28.53 would be a bearish reversal. With a beta of 1.293, Bruker is about 29% more volatile than the S&P 500, meaning it amplifies market moves and requires careful risk management.
Beta
1.29
1.29x market volatility
Max Drawdown
-39.9%
Largest decline past year
52-Week Range
$29-$65
Price range past year
Annual Return
+43.8%
Cumulative gain past year
| Period | BRKR Return | S&P 500 |
|---|---|---|
| 1m | +5.8% | +2.0% |
| 3m | +61.2% | +10.6% |
| 6m | +11.2% | +8.3% |
| 1y | +43.8% | +20.4% |
| ytd | +25.9% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BRKR Fundamental Analysis
Bruker's revenue trajectory shows mixed signals: the most recent quarter (Q4 2025) reported revenue of $977.2 million, a slight YoY decline of -0.24% from $979.6 million in Q4 2024. Over the trailing four quarters, revenue has fluctuated between $797.4 million and $977.2 million, with the Q4 2025 figure being the highest in the period. The company's revenue growth appears to be stagnating, with the most recent quarter showing a marginal decline, which raises concerns about top-line momentum. However, the BSI CALID segment remains the primary revenue driver, and the company's diversified portfolio may provide stability. Bruker is marginally profitable, with net income of $26 million in Q4 2025, but the trailing twelve months net income is negative (EPS of -$0.0012). Gross margin improved to 47.77% in Q4 2025 from 44.88% in Q3 2025, indicating some operating leverage. However, net margin remains thin at 2.66% in Q4 2025, and the company has reported negative net income in two of the last four quarters, highlighting inconsistent profitability. The balance sheet shows a debt-to-equity ratio of 0.83, indicating moderate leverage. Free cash flow for Q4 2025 was $207.2 million, a significant improvement from negative free cash flow in prior quarters. The current ratio of 1.73 suggests adequate liquidity, and ROE is negative at -0.35%, reflecting the company's inconsistent earnings. Overall, Bruker generates sufficient cash to fund operations but has relied on debt financing for growth.
Quarterly Revenue
$977200000.0B
2025-12
Revenue YoY Growth
-0.24%
YoY Comparison
Gross Margin
47.77%
Latest Quarter
Free Cash Flow
$43300000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BRKR Overvalued?
Given that Bruker's trailing twelve-month net income is negative (EPS -$0.0012), the trailing PE ratio is not meaningful. Therefore, we use the price-to-sales (PS) ratio as the primary valuation metric. The trailing PS ratio is 2.08x, while the forward PE (based on positive earnings estimates) is 25.3x. The gap between the negative trailing PE and positive forward PE implies the market expects a return to profitability, which is reflected in the forward multiple. Compared to the industry average (not provided, but typically for medical devices, PS ratios range from 2-5x), Bruker's PS of 2.08x appears reasonable, potentially at a discount if the industry average is higher. However, without explicit industry data, we note that the PS ratio is below the company's historical average. Historically, Bruker's PS ratio has ranged from 7.3x (Q4 2025) to 20.1x (Q2 2021), with the current 2.08x significantly below that range. This suggests the stock is trading at a historically low multiple, which could indicate a value opportunity or reflect fundamental deterioration. The low PS ratio relative to history may be due to the recent earnings weakness, but if profitability improves, multiple expansion could drive upside.
PE
-314.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -21x~302x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: BRKR's inconsistent profitability is a key risk, with negative TTM EPS and net losses in two of the last four quarters. The company's net margin of 2.66% in Q4 2025 is thin, and ROE is negative at -0.35%, indicating poor returns on equity. Revenue growth has stagnated, with Q4 2025 revenue declining 0.24% YoY, and the company relies on debt financing (debt-to-equity 0.83) to fund operations, though free cash flow improved to $207.2M in Q4. If revenue fails to reaccelerate, the company may struggle to achieve the profitability needed to justify its forward PE of 25.3x.
Market & Competitive Risks: The stock's beta of 1.293 makes it highly sensitive to market downturns, and its elevated short ratio of 4.36 days suggests significant bearish positioning. Valuation risk is pronounced: the trailing PS of 2.08x is low historically, but the forward PE of 25.3x implies high expectations for earnings growth. If the company fails to meet EPS estimates, the stock could de-rate sharply. Competitive pressures in the scientific instruments market could also pressure margins and market share.
Worst-Case Scenario: If BRKR fails to deliver the expected earnings recovery due to continued revenue declines or margin compression, the stock could fall to its 52-week low of $28.53, representing a -53.7% decline from the current price of $61.64. This scenario could be triggered by a major earnings miss, loss of a key customer, or a broad market sell-off given the stock's high beta. The historical max drawdown of -39.85% provides a reference for potential downside.
FAQ
The key risks are: 1) Financial risk: negative TTM EPS and inconsistent profitability, with net margin of only 2.66% in Q4 2025. 2) Revenue risk: flat to declining revenue (-0.24% YoY in Q4 2025) could persist, preventing earnings recovery. 3) Valuation risk: the forward PE of 25.3x relies on achieving EPS estimates; a miss could cause a sharp de-rating. 4) Market risk: beta of 1.293 amplifies downside in a market sell-off, and the short ratio of 4.36 days indicates bearish sentiment. The most severe risk is a -53.7% decline to the 52-week low of $28.53 if earnings disappoint.
The 12-month forecast is mixed: the bull case (30% probability) targets $75-$90, driven by earnings beat and multiple expansion. The base case (50% probability) sees the stock trading in a $60-$75 range, with EPS in line with consensus of $3.51. The bear case (20% probability) targets $35-$50, with EPS falling short. The most likely scenario is the base case, assuming modest revenue growth and stable margins. The analyst consensus average target of ~$88.80 implies +44% upside, but this is contingent on a successful earnings recovery.
BRKR's valuation is mixed: on a trailing basis, the negative PE makes it unappealing, but the forward PE of 25.3x is reasonable for a healthcare technology company. The PS ratio of 2.08x is well below the historical range of 7.3x-20.1x, suggesting the stock is undervalued relative to its own history. However, this low PS may reflect the recent earnings weakness. Compared to the industry (medical devices, typical PS 2-5x), BRKR's PS is at the lower end, indicating potential value. The market is pricing in a return to profitability, so the stock is fairly valued if earnings materialize, but overvalued if they don't.
BRKR offers a compelling risk/reward for investors who believe in its earnings recovery story, with analyst targets implying +44% upside from $61.64. However, the stock is not a good buy for conservative investors due to its negative TTM earnings, high beta of 1.293, and stagnant revenue growth. The forward PE of 25.3x is reasonable if EPS reaches $3.51, but any disappointment could lead to sharp downside. It is a good buy for those with a high risk tolerance and a 12-month horizon, but only if they are comfortable with the possibility of a -50% drawdown to the 52-week low of $28.53.
BRKR is more suitable for short-to-medium-term investment (6-12 months) given its speculative nature and dependence on near-term earnings catalysts. The stock's high beta (1.293) and short ratio (4.36 days) make it volatile, which can benefit active traders but is risky for long-term holders. The lack of consistent profitability and dividend (yield 0.32%) makes it unattractive for long-term income or value investors. A minimum holding period of 12 months is recommended to allow for the earnings recovery to materialize, but investors should set strict stop-losses given the downside risk.